Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lexaria Bioscience ( (LEXX) ) has provided an announcement.
Lexaria Bioscience Corp. announced partial final results from a human study comparing their oral DehydraTECH-tirzepatide to Eli Lilly’s injected Zepbound®. The study revealed that the oral formulation reduced adverse events by 47% and gastrointestinal-related adverse events by 54% compared to the injected version, while maintaining comparable efficacy in blood glucose reduction and insulin secretion. These results suggest that Lexaria’s oral drug delivery system may offer a more tolerable alternative for diabetes treatment, potentially strengthening its market position in the pharmaceutical industry.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the effectiveness and tolerability of various pharmaceuticals.
YTD Price Performance: -10.43%
Average Trading Volume: 154,929
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $37.7M
For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.
